Jianfeng Group Lin2016 -006 (Announcement of 906 Board Resolution)
Release time:
2020-08-05
证券代码:600668 证券简称:尖峰集团 编号:临2016-006
债券简称:13尖峰01 债券代码:122227
债券简称:13尖峰02 债券代码:122344
浙江尖峰集团股份有限公司
九届六次董事会决议公告
本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏,并对其内容的真实性、准确性和完整性承担个别及连带责任。
一、董事会会议召开情况
(一)本次董事会会议的召集、召开符合有关法律、法规及公司《章程》的相关规定。
(二)2016年3月28日,公司以传真、电子邮件及专人送达的方式发出了本次董事会会议通知。
(三)2016年4月8日,本次董事会会议在浙江省金华市尖峰大厦三楼会议室以现场表决方式召开。
(四)本次董事会会议应出席的董事8人,实际出席会议的董事8人,会议有效表决票数8票。
(五)本次董事会由董事长蒋晓萌主持,公司监事和高级管理人员列席会议。
二、董事会会议审议情况
1、通过了2015年度总经理业务报告
经审议,董事会一致通过了该报告。
表决结果:同意8票、反对0票、弃权0票。
2、通过了2015年度财务决算报告
董事会审议并通过了该报告,本议案需提交股东大会审议。
表决结果:同意8票、反对0票、弃权0票。
3、通过了2015年度利润分配议案
经天健会计师事务所审计,2015年度公司合并报表归属于母公司股东的净利润为200,899,362.77 元;母公司会计报表净利润140,843,091.13元。按母公司的本期净利润140,843,091.13元为基数,提取10%法定公积金14,084,309.11元,加年初未分配利润407,611,924.40元,减去2014年度现金分红86,020,957.00元,本年度可供分配利润为448,349,749.42元。
公司2015年度拟进行现金分配,以2015年末股本344,083,828股为基数,每10股派发现金红利1.80元(含税),向股权登记日登记在册的全体股东派发现金股利总额为61,935,089.04元(含税)。
2015年度不进行公积金转增股本。
该预案将提交股东大会审议。
表决结果:同意8票、反对0票、弃权0票。
4、通过了聘请公司2016年度审计机构的议案
董事会审议并通过了该议案,同意聘请天健会计师事务所为公司2016年度财务及内部控制审计机构。本议案需提交股东大会审议。
表决结果:同意8票、反对0票、弃权0票。
5、通过了2015年年度报告及其摘要
董事会审议并通过了该报告,本议案需提交股东大会审议。
表决结果:同意8票、反对0票、弃权0票。
2015年度报告全文及摘要详见上海证券交易所网站(www.sse.com.cn)。
6、通过了关于对控股子公司提供担保的议案
董事会一致通过了该议案,同意为控股子公司提供以下担保事宜。
(1)对控股子公司向金融机构借款提供担保,设定如下额度:
|
被担保单位 |
设定担保额度(万元) |
|
大冶尖峰水泥有限公司 |
10000 |
|
浙江尖峰药业有限公司 |
30000 |
|
金华市医药公司 |
15000 |
|
浙江尖峰国际贸易有限公司 |
5000 |
|
云南尖峰水泥有限公司 |
5000 |
|
合计 |
65000 |
(2)同意为浙江尖峰国际贸易有限公司提供担保函,为浙江尖峰国际贸易有限公司的客户在该公司存放的货物提供相应的担保。
在以上额度内的担保授权董事长分次执行。
本议案需提交股东大会审议。
表决结果:同意8票、反对0票、弃权0票。
详见《对控股子公司提供担保的公告》(临2016-008)。
7、通过了与浙江凯恩特种材料股份有限公司互相担保的议案
董事会审议并通过了该议案,同意与浙江凯恩特种材料股份有限公司进行额度为5000万元、期限为一年的等额互保。
本议案需提交股东大会审议。
表决结果:同意8票、反对0票、弃权0票。
详见《与浙江凯恩特种材料股份有限公司互相担保的公告》(临2016-009)。
8、通过了2015年度内部控制评价报告
董事会审议并通过了该报告。
表决结果:同意8票、反对0票、弃权0票。
内部控制评价报告详见上海证券交易所网站(www.sse.com.cn)。
9、通过了关于修改内控手册的议案
董事会审议并通过了该议案,同意对内控手册中的部分制度进行修订。
表决结果:同意8票、反对0票、弃权0票。
本次修订的内控手册中的《尖峰集团筹资管理制度》和《尖峰集团对外投资管理制度》详见上海证券交易所网站(http://www.sse.com.cn)。
10、通过了2015年度《中长期激励基金计提方案》
董事会审议并通过了该议案。根据《中长期激励管理办法》的规定,提取2015年度中长期激励基金为6213382.35元。
表决结果:同意8票、反对0票、弃权0票。
11、通过了关于增补独立董事的议案
董事会审议并通过了该议案。公司董事会同意提名孙宏斌先生为本公司独立董事候选人,提交股东大会选举。简历见附件。
表决结果:同意8票、反对0票、弃权0票。
12、通过了关于对天士力集团增资的关联交易议案
董事会审议并通过了该议案。关联董事蒋晓萌先生、杜自弘先生回避了该项议案的表决。
表决结果:同意6票、反对0票、弃权0票。
该报告将提交股东大会审议。
详见《关于对天士力集团增资的关联交易公告》(临2016-010)。
13、通过了关于对尖峰药业增资的关联交易议案
董事会审议并通过了该报告。关联董事蒋晓萌先生回避了该项议案的表决。
表决结果:同意7票、反对0票、弃权0票。
详见《关于对尖峰药业增资的关联交易公告》(临2016-011)。
公司独立董事事前对第12、13两个事项进行了审议,认为:上述两项关联交易的增资价格依据经审计的净资产决定,且按各股东持股比例享有增资权,公司参与增资后能确保不降低所占的股权份额。上述关联交易实施后将有效优化被投资公司的资产结构,增强企业实力、提升竞争力,确保企业持续健康发展。以上关联交易没有损害公司及股东的利益,同意将该议案提交给公司第九届董事会第6次会议审议。
董事会审计委员会对第12、13两个事项发表了审核意见:认为上述关联交易属于公司正常的经济行为,符合公司经营发展需要;增资的价格都依据经审计的净资产决定,且按各股东持股比例享有增资权,增资后本公司所占被投资单位的股权份额不会下降;交易遵循了公平、公正、自愿、诚信的原则,没有损害公司及股东的利益,予以同意。
14、通过了关于召开2015年度股东大会的议案
董事会决定于2016年5月9日在浙江省金华市婺江东路88号尖峰大厦召开2015年度股东大会。
表决结果:同意8票、反对0票、弃权0票
详见《关于召开2015年度股东大会的通知》(临2016-012)。
15、通过了2015年度独立董事述职报告
董事会审议并通过了该报告。
表决结果:同意8票、反对0票、弃权0票
独立董事将向股东大会报告。
16、通过了董事会审计委员会2015年度履职报告
董事会审议并通过了该报告。
表决结果:同意8票、反对0票、弃权0票
17、通过了2015年度董事会工作报告
表决结果:同意8票、反对0票、弃权0票。
该报告将提交股东大会审议。
公司独立董事的独立意见:
公司独立董事对上述3、4、6、7、10、11、12、13八项决议发表了独立意见,认为:该决议的形成符合《公司法》、公司《章程》等有关规定,没有损害中小股东的利益。
三、上网公告附件
公司第九届独立董事对上述相关事项的独立董事意见,对关联交易事项的事前认可声明;审计委员会对关联交易事项的书面审核意见。
特此公告
浙江尖峰集团股份有限公司董事会
二〇一六年四月十二日
附件:
孙宏斌先生,1966年12月出生,理学博士、教育部“长江学者”特聘教授。先后在中科院上海有机化学研究所、德国亚琛工业大学和美国佛罗里达大学从事博士后研究工作,在美国加州Metabolex公司从事新药研究工作。现任中国药科大学教授、博士生导师、新药研究中心主任,兼任江苏省代谢性疾病药物重点实验室主任、“天然药物活性组分与药效”国家重点实验室副主任、中国药学会药物化学专业委员会委员、江苏省药学会药物化学专业委员会副主任委员、中国药科大学学位评定委员会和学术委员会委员、国家基金委医学部“十三五”发展战略研究“药物学”专家组副组长、国家技术发明奖会议评审专家、江苏威凯尔医药科技有限公司名誉董事长等职。
More information
Pharmaceutical Company Established New Drug R & D Promotion Committee
Recently, the new drug research and development promotion committee of Jianfeng pharmaceutical company was formally established, which will be responsible for promoting the new drug research and development progress of pharmaceutical companies and subordinate enterprises, and coordinating the new drug research and development work of various departments and subordinate enterprises. The New Drug Promotion Committee is headed by Huang Jinlong, deputy general manager of the group and general manager of the pharmaceutical company, and Jiang Hong, deputy general manager of the pharmaceutical company, is headed by Pang Xiong, Shi Cunyuan, Xu Lizhen, Yu Jingjing, Zheng Kunwu, Feng Lixiang, Kang Litao, Li Qian, Wu Chonggui, Zhai Tsunami, Huang Fang and Tong Xiaojun. The committee has an office, and Shi Cunyuan is also the director of the office, responsible for the supervision, communication, and coordination of the company's new drug research and development projects. The main responsibilities of the new drug promotion committee include: organizing the establishment and improvement of the R & D project management system and relevant regulations of the pharmaceutical company; organizing the formulation of the development plan of the new drug R & D project of the pharmaceutical company and supervising the implementation; making decisions on project initiation and participating in project evaluation; supervising the management of new drug R & D of the pharmaceutical company and providing guidance; Responsible for the process management of new drug R & D projects and the promotion and coordination of new drug R & D; carry out the assessment of new drug research and development projects; issue the responsibility system assessment and task statement of new drug research and development projects; be responsible for solving major technical problems in the process of new drug research and development; be responsible for the research and improvement of the management mode of research and development projects of pharmaceutical companies; be responsible for the future trend analysis of new drug research and development projects; review the major scientific research achievements of pharmaceutical companies and put forward reward suggestions. Huang Jinlong said that the research and development of new drugs is an important foundation for the healthy development of the pharmaceutical industry and is a systematic project. Jianfeng Pharmaceutical has always attached great importance to the research and development of new drugs, but there is still a certain gap between the progress of research and development and the development process of the enterprise, and the lack of coordination in the research and development process also affects the progress and quality of new drug research and development to a certain extent. The purpose of the establishment of the New Drug Research and Development Promotion Committee is to solve the progress of new drug research and development, to find and solve problems in time, to implement more targeted, and to effectively integrate enterprise resources, improve the speed and quality of new drug research and development, and make good product reserves for the healthy development of pharmaceutical companies. (Reporter Ni Yingzhen)
2020
09-11
Jianfeng Pharmaceutical ranks among the top 100 Chinese pharmaceutical industries in 2019
On August 25, the "2019 Top 100 Series List of China's Pharmaceutical Industry" was released in Kunming. Zhejiang Jianfeng Pharmaceutical Company was shortlisted as one of the top 100 enterprises in China's pharmaceutical industry. The product Berunning (Olopatadine Hydrochloride Eye Drops) was selected as the "Most Growing Product Brand" of China's pharmaceutical industry ". The "Top 100 Pharmaceutical Industry Series List" was evaluated and released by Guangzhou Punctuation Pharmaceutical Information Co., Ltd., a subsidiary of the Southern Institute of Pharmaceutical Economics of the State Drug Administration, and is known as the "Oscar in Chinese Pharmaceutical Industry. Southern Institute is the earliest institution in China that specializes in pharmaceutical industry policy and market economy research, pharmaceutical market research, pharmaceutical economic data analysis and research, and pharmaceutical professional media publishing. It is in the field of market information value-added services and media communication and marketing services in China's pharmaceutical and health industry., The field of professional quality improvement has extremely extensive influence. The "Top 100 Pharmaceutical Industry" is comprehensively evaluated by the company's annual pharmaceutical industry sales revenue, total profit and R & D investment results. On the same day, the "most growing product brand" of Chinese medicine selected by the Southern Institute's media "Pharmaceutical Economic News" was released simultaneously. Spike Pharmaceuticals product Beirunning (Olopatadine Hydrochloride Eye Drops) was selected. (Xu Yuting)
2020
09-01
Company Disclosure 2020 Semi-Annual Report
On August 28, the Group held the 16th meeting of the 10th Board of Directors of the Company by means of communication, and considered and adopted the "2020 Semi-Annual Report of Jianfeng Group" and the "Proposal on Changes in the Company's Accounting Policy". On August 29, the Company's 2020 semi-annual report was publicly disclosed on the Shanghai Stock Exchange and the Shanghai Securities News and China Securities News. In the first half of the year, the Group focused on the general policy of "grasping projects, making up for shortcomings, improving quality and efficiency, and constantly improving the core competitive advantage", and on the basis of doing a good job in epidemic prevention and control, the Group seized the resumption of work and production, accelerated project construction, and enhanced the core competitiveness of enterprises. In the first half of 2020, the company achieved total operating income of 1.44 billion yuan, net profit attributable to shareholders of 0.368 billion yuan, net profit per share of 1.07 yuan. As of the end of June 2020, the Company's total assets were $5.892 billion, net assets were $4.068 billion, and net assets per share were $11.82. From February to April, affected by the epidemic, the national project construction progress slowed down, cement market demand decreased; after May, the epidemic was effectively controlled, infrastructure investment continued to recover, the real estate industry continued to pick up, cement sales steadily rebounded. During the outbreak, Daye Peak completed the technical transformation projects such as the cold machine, cement mill, into the desulfurization tower anti-corrosion transformation, to ensure the efficient operation of the production equipment after the resumption of work. Yunnan peak rotary kiln production, cement production and other major technical and economic indicators of steady rise; comply with market trends, timely adjustment of marketing policies. Guizhou Jianfeng has promoted the project infrastructure construction, equipment installation and commissioning, raw material bidding and other work in an orderly manner, and through preliminary publicity to enhance the popularity of the Jianfeng brand in the local area, and make a series of preparations for the transformation from project construction to production and operation. In the first half of 2020, the reform of China's medical and health system continued to deepen, and new policies were introduced intensively. Peak Pharmaceuticals and its subsidiaries in the epidemic prevention work at the same time in the first time to achieve the resumption of production, and actively organize donations to support the fight against the epidemic, was named the annual "war epidemic star" the most socially responsible pharmaceutical enterprises. In the first half of the year, Jianfeng Pharmaceutical continued to increase the introduction and development of varieties, and JFAN-1001 applied for clinical application of new anti-tumor drugs. At present, it has obtained the notice of approval for clinical trials. Optimize the production process of API workshop and further shorten the production cycle of raw materials. Continue to improve product sales policies and strengthen market channel control. Shanghai North Carolina further straightened out the internal management structure, production and marketing convergence more smoothly, continue to promote the construction of Anhui North Carolina and Anhui Zhongwang Phase II technical transformation project, promote the peak pharmaceutical raw materials, preparations integration of industrial upgrading strategy. Other business segments of the company actively responded to the challenge of the new crown epidemic and carried out production and operation activities in a standardized and orderly manner. Tianjin natural products company vigorously explore the international and domestic markets, sales revenue to achieve steady growth. Peak Health focuses on the basic idea of "sales orientation, burden reduction and efficiency improvement, fine-grained savings, cost reduction and efficiency enhancement" to effectively improve the operational efficiency of enterprises. Jianfeng International Trade has actively developed new storage business varieties and achieved practical results, and has become the first enterprise in Jinhua to formally obtain the qualification of "network freight. Peak cable seizes the special needs of communication cables such as subways, vigorously promotes large logarithmic cables for subways, and strives to achieve the long tail effect. On the same day, the company also held the 10th meeting of the Ninth Board of Supervisors and reviewed and approved relevant reports. (residual fruit)
2020
09-01
The company organizes new employee induction training
From August 12 to 14, in order to strengthen the training of talents in the group and improve the comprehensive quality of new employees, Jiang Xiaomeng, secretary of the party committee and chairman of the group company, Yu Jianhong, general manager, and other leaders and heads of relevant enterprises and departments conducted a three-day induction training for new employees. New employees from foreign enterprises such as Guizhou Huangping Peak, Daye Peak and Shanghai North Carolina participated simultaneously through online methods. In the course of corporate culture, General Manager Yu Jianhong started from the history of the development and struggle of the peak, divided into five stages: hard work, determined reform, diversified development, strategic adjustment, and strategic development, and introduced in detail the development process of the group company and the current industrial layout., The results achieved; from the aspects of enterprise spirit, vision, development philosophy, values, business philosophy, etc, this paper introduces the peak corporate culture rooted in 62 years of history and inherited in the blood; from the perspective of an enterprise manager and old employees, he speaks a lot of truth to the new employees and puts forward a lot of hopes and suggestions. Chairman Jiang Xiaomeng took "How New Employees Achieve Win-Win with Enterprises" as the topic, and proposed that the key to the success of an enterprise lies in how to select, retain, educate and employ people. Peak and employees complement each other. Peak can achieve today's achievements and the struggle of generations of peak people are inseparable. He also taught new employees the basic concepts that need to be understood, the basic qualities that need to be possessed and the sense of hardship in entering the new environment through 16 key words, and combined with his own experience and quoting from others, he analyzed the core elements of success, the signs of a successful career, the personal qualities that need to be possessed for success, and the importance of establishing a personal knowledge management system, it expresses the ardent hope of new employees to adjust their mentality, keep learning, clear goals, clear dreams, cultivate win-win thinking, and grow up together with the peak. The heads of the human resources department of the group company, the safety management office of the group company, and the comprehensive department of the pharmaceutical company also taught the new employees the corporate rules and regulations and the "Employee Handbook", safety knowledge and professional ethics. The new employees also visited the group exhibition hall and had a deeper understanding of the development history and enterprise achievements of the peak. After the training, the human resources department also organized an examination to test the training effect. (Reporter Chen Shengmu)
2020
08-21
According to this newspaper, through the interconnection monitoring of the transportation department in Zhejiang province, the network freight platform of peak international trading company passed the online service capability audit, interface access audit, eight capability identification and other audit procedures, and successfully obtained the road transportation business license with the qualification of "network freight" on July 2. It is understood that Jianfeng International Trade is currently the first enterprise in Jinhua and Quzhou to obtain this qualification.
2020
08-05
News from our newspaper On July 21, Xi Jinping, General Secretary of the Central Committee of the Communist Party of China, President of the State, and Chairman of the Central Military Commission hosted a symposium for entrepreneurs in Beijing and delivered an important speech. Over the past few days, the General Secretary's speech has aroused strong repercussions in all walks of life. On July 23, Jiang Xiaomeng, chairman of the group company, said in an interview with Jinhua TV that the general secretary's speech was calm and inspiring, and pointed out the direction of future work for entrepreneurs.
2020
08-05